Dr Marie Ann RoskrowChairperson
Dr Roskrow gained a BSc(Hons), MBBS (Hons) degree and a PhD in Immunology from the University of London. She has more than 25 years of experience as a physician / medical researcher, investment banker, CEO and chairperson in both private and listed companies such as the GSF Research Institute (Munich), Patrys Ltd (Melbourne), Imevax (Munich) and Lazard Healthcare Investment Banker (New York, San Francisco, Sydney). During her 8 years at Lazard, Marie executed a wide-range of complex strategic transactions including: mergers and acquisitions, joint ventures and asset divestitures. Additionally she was involved in the execution of > 50 financing deals including: IPOs, capital raisings and structured debt. Marie holds 0 shares in Biotec Pharmacon
Mr. Reinemo has an MBA from the University of Chicago and has more than 25 years of experience within consultancy and investments from companies such as McKinsey, Kistefos, Creo Partners and Siljan Industrier. Arne has extensive board experience through several board positions, including chairman of Nextgentel and TopTemp Holding. Arne holds 0 shares in Biotec Pharmacon
Ms. Rydin (born 1957) holds a Master of Science degree from Chalmers University of Technology, Sweden. Ms. Rydin was elected to the Board in 2014. Her latest assignments have been as CEO of entrepreneurial companies in the Life Science and Health Care industry. Before this she was serving as VP Wound & Skin Care Global Marketing of Coloplast and Managing Director of the Mölnlycke Health Care subsidiary in Eastern Europe. Ms. Rydin started her career in SCA Hygiene / Mölnlycke in 1981 in Research & Development and has held a range of management positions in Marketing & Sales. Rydin holds no shares in Biotec Pharmacon.
Martin has over 30 years experience in the medtech industry in large multi-nationals, start-ups and public companies. He has served as a Board member in a variety of life science companies encompassing medical devices, diagnostics and biotech. Martin is a member of the NIHR Strategy Board. After 15 years in increasingly senior roles in large multi-nationals, Martin became CEO of biomaterials company Tissue Science Laboratories, which he took from start-up, through angel capital and a listing on London’s AiM market to trade sale to Covidien. Martin has considerable experience of the establishment and funding of early stage life science ventures and to date has raised over £50m to support the commercialisation of novel technologies. Mr Hunt holds no shares in Biotec Pharmacon.
Ms. Skjæveland (born 1977) holds a Civil Engineer in Biotechnology and a PhD in Immunology from the University of Tromsø. Skjæveland worked as post.doc and a researcher at the University of Tromsø before she joined Biotec BetaGlucan in 2013 as a Scientific Product manager for Woulgan. She was elected as employee representative to the Board in May 2017. Number of shares in Biotec Pharmacon held by Ms. Skjæveland: 16,087. Number of options: 10,000.